Bristol-Myers Wins U.K. Nod for Melanoma Drug Despite Cost

  • Recommendation follows NICE rejection for use in lung cancer
  • Final draft guidance is being reviewed by consultation group

Bristol-Myers Squibb Co. won the endorsement of the U.K.’s health-cost regulator for the use of its drug Opdivo in skin-cancer patients after failing to win its recommendation for treating lung tumors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.